{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:20Z","timestamp":1787008700073,"version":"build-2736575974"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Injection site reactions (ISRs) are known side effects of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor alirocumab. Transient ISR to alirocumab after a long phase of good tolerability have not been reported previously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 55-year-old woman (Patient 1) and a 77-year-old man (Patient 2) were treated with alirocumab for the management of dyslipidaemia. Both patients tolerated the treatment without side effects for 7 and 2 months, respectively. After an upper respiratory tract infection in Patient 1 and a first COVID-19 vaccination in Patient 2, both patients suddenly developed ISR with erythema, calor, and itching upon 2 (Patient 1) and 1 (Patient 2) subsequent injection(s), respectively. Symptoms resolved with local steroids, oral antihistamines, and cooling. After termination of the presumed immune system activated state, alirocumab was well tolerated again in both patients without recurrence of any ISR upon repeated applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These are the first cases to report transient ISR to a PCSK9 inhibitor, possibly triggered by activation of the immune system, after prolonged good tolerability. Based on the transient and benign nature of the reaction, such patients should be encouraged to continue supervised treatment, as tolerability may return after resolution of the pro-inflammatory state.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytac187","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T17:07:29Z","timestamp":1651770449000},"source":"Crossref","is-referenced-by-count":5,"title":["Transient injection site reaction to alirocumab during immune system activation: a case series"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0045-6596","authenticated-orcid":false,"given":"Sarah","family":"B\u00e4r","sequence":"first","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"R\u00e4ber","sequence":"additional","affiliation":[{"name":"Dermatologie Thun, Thun, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C.","family":"Koskinas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schlapbach","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-3026","authenticated-orcid":false,"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"2022051715244969800_ytac187-B1","first-page":"111","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"2020","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"2022051715244969800_ytac187-B2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"2021","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2022051715244969800_ytac187-B3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjcvp\/pvaa024","article-title":"Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis","volume":"7","author":"Guedeney","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022051715244969800_ytac187-B4","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022051715244969800_ytac187-B5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022051715244969800_ytac187-B6","doi-asserted-by":"crossref","first-page":"e12817","DOI":"10.1111\/dth.12817","article-title":"Injection site reactions with the use of biological agents","volume":"32","author":"Thomaidou","year":"2019","journal-title":"Dermatol Ther"},{"key":"2022051715244969800_ytac187-B7","first-page":"212","article-title":"Hypersensitivity reactions to biological drugs","volume":"24","author":"Corominas","year":"2014","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2022051715244969800_ytac187-B8","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-017-0752-8","article-title":"Pathomechanisms of Contact Sensitization","volume":"17","author":"Esser","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"2022051715244969800_ytac187-B9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease","volume":"7","author":"Mocci","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022051715244969800_ytac187-B10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000087013","article-title":"Cutaneous adverse events of biological therapy for psoriasis: review of the literature","volume":"211","author":"Thielen","year":"2005","journal-title":"Dermatol Basel Switz"},{"key":"2022051715244969800_ytac187-B11","first-page":"893","article-title":"Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein","volume":"137","author":"Zeltser","year":"2001","journal-title":"Arch Dermatol"},{"key":"2022051715244969800_ytac187-B12","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1398-9995.2011.02652.x","article-title":"Mechanisms of chemical-induced innate immunity in allergic contact dermatitis","volume":"66","author":"Martin","year":"2011","journal-title":"Allergy"},{"key":"2022051715244969800_ytac187-B13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2133.2009.09106.x","article-title":"Guidelines for the management of contact dermatitis: an update","volume":"160","author":"Bourke","year":"2009","journal-title":"Br J Dermatol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytac187\/43549248\/ytac187.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/6\/5\/ytac187\/43707988\/ytac187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/6\/5\/ytac187\/43707988\/ytac187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T14:40:39Z","timestamp":1652798439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytac187\/6580680"}},"subtitle":[],"editor":[{"given":"David","family":"Oxborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Adam","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Tina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Reshma","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Katharine","family":"Kott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytac187","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,5,1]]},"article-number":"ytac187"}}